Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

Reply to J.-H. Choi et al.

Bachelot T, Cropet C, Ray-Coquard I, Pujade-Lauraine E.

J Clin Oncol. 2013 Feb 1;31(4):511. No abstract available.

PMID:
23472262
[PubMed - indexed for MEDLINE]
Free Article
2.

Appropriate design of prospective studies.

Choi JH, Jung SH.

J Clin Oncol. 2013 Feb 1;31(4):510-1. doi: 10.1200/JCO.2012.46.0980. Epub 2012 Dec 26. No abstract available.

PMID:
23269994
[PubMed - indexed for MEDLINE]
Free Article
3.

Reversing hormone resistance: have we found the golden key?

Rugo HS, Keck S.

J Clin Oncol. 2012 Aug 1;30(22):2707-9. doi: 10.1200/JCO.2012.42.1271. Epub 2012 Jul 2. No abstract available.

PMID:
22753913
[PubMed - indexed for MEDLINE]
Free Article
4.

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaƫth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E.

J Clin Oncol. 2012 Aug 1;30(22):2718-24. doi: 10.1200/JCO.2011.39.0708. Epub 2012 May 7.

PMID:
22565002
[PubMed - indexed for MEDLINE]
Free Article
5.

The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.

Ryan PD, Goss PE.

Nat Clin Pract Oncol. 2005 Dec;2(12):596-7. No abstract available.

PMID:
16341095
[PubMed - indexed for MEDLINE]
6.

Everolimus in HR-positive advanced breast cancer.

Tartarone A, Lerose R, Aieta M.

N Engl J Med. 2012 May 3;366(18):1739; author reply 1739-40. doi: 10.1056/NEJMc1202719#SA2. No abstract available.

PMID:
22551140
[PubMed - indexed for MEDLINE]
7.

Everolimus in HR-positive advanced breast cancer.

Massarweh S, Croley J, Weiss H.

N Engl J Med. 2012 May 3;366(18):1738-9; author reply 1739-40. doi: 10.1056/NEJMc1202719#SA1. No abstract available.

PMID:
22551139
[PubMed - indexed for MEDLINE]
8.

The evolving role of endocrine therapy for early stage breast cancer.

Manders JB, Gradishar WJ.

Breast Cancer. 2005;12(2):62-72. Review. No abstract available.

PMID:
15858435
[PubMed - indexed for MEDLINE]
Free Article
9.

Adjuvant treatment for early breast cancer.

Smith I.

Ann Oncol. 2005;16 Suppl 2:ii182-7. Review. No abstract available.

PMID:
15958454
[PubMed - indexed for MEDLINE]
Free Article
10.

Moving away from the "one shoe fits all" strategy: the key to future progress in chemotherapy.

Piccart-Gebhart MJ.

J Clin Oncol. 2005 Mar 10;23(8):1611-3. No abstract available.

PMID:
15755965
[PubMed - indexed for MEDLINE]
Free Article
11.

Comment on Wang et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.

Li J, Yao Y, Jing J.

Tumour Biol. 2014 Jul;35(7):6183. doi: 10.1007/s13277-014-1924-y. Epub 2014 Apr 9. No abstract available.

PMID:
24715305
[PubMed - indexed for MEDLINE]
12.

Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.

Burstein HJ, Griggs JJ.

J Clin Oncol. 2012 Mar 1;30(7):684-6. doi: 10.1200/JCO.2011.40.1455. Epub 2012 Jan 23. No abstract available.

PMID:
22271478
[PubMed - indexed for MEDLINE]
Free Article
13.

Using HER2 to choose chemotherapy in breast cancer: is it ready for the clinic?

McNeil C.

J Natl Cancer Inst. 1999 Jan 20;91(2):110-2. No abstract available.

PMID:
9923848
[PubMed - indexed for MEDLINE]
Free Article
14.

Tamoxifen or aromatase inhibitors in breast cancer: efficacy and safety.

Neven P, Van Den Broecke R.

Acta Chir Belg. 2007 Jun;107(3):240-56. Review. No abstract available.

PMID:
17685248
[PubMed - indexed for MEDLINE]
15.

Paclitaxel, not bevacizumab, was primarily responsible for the favorable effects seen in the RIBBON-2 trial.

Kesikli A, Kilickap S.

J Clin Oncol. 2012 Feb 1;30(4):461; author reply 461-2. doi: 10.1200/JCO.2011.40.2305. Epub 2011 Dec 27. No abstract available.

PMID:
22203773
[PubMed - indexed for MEDLINE]
Free Article
16.

HER2 and response to paclitaxel in node-positive breast cancer.

Mehta R.

N Engl J Med. 2008 Jan 10;358(2):197-8; author reply 198. No abstract available.

PMID:
18193531
[PubMed - indexed for MEDLINE]
17.

A practical overview of aromatase inhibitors.

Younus J, Vandenberg TA.

Anticancer Res. 2005 May-Jun;25(3c):2497-502. Review.

PMID:
16080483
[PubMed - indexed for MEDLINE]
Free Article
18.

Anthracyclines in the treatment of HER2-negative breast cancer.

Paik S, Taniyama Y, Geyer CE Jr.

J Natl Cancer Inst. 2008 Jan 2;100(1):2-4. Epub 2007 Dec 25. No abstract available.

PMID:
18159066
[PubMed - indexed for MEDLINE]
Free Article
19.

Breast-cancer therapy--looking back to the future.

Moore A.

N Engl J Med. 2007 Oct 11;357(15):1547-9. No abstract available.

PMID:
17928605
[PubMed - indexed for MEDLINE]
20.

ATAC trial update.

Del Mastro L, Venturini M.

Lancet. 2005 Apr 2-8;365(9466):1225; author reply 1225-6. No abstract available.

PMID:
15811447
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk